Research programme: antibacterial therapeutics - AimMax Therapeutics
Alternative Names: Atypical community acquired bacterial pneumonia therapeutics - AimMax Therapeutics; Methicillin-resistant Staphylococcus aureus infection therapeutics - AimMax TherapeuticsLatest Information Update: 04 May 2023
At a glance
- Originator AimMax Therapeutics
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 24 Apr 2023 Early research in Community-acquired pneumonia in USA (unspecified route) prior to April 2023 (AimMax Therapeutics pipeline, April 2023)
- 24 Apr 2023 Early research in Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route) prior to April 2023 (AimMax Therapeutics pipeline, April 2023)